Home  /  Resources


The GRID Hamilton Rating Scale for Depression (GRID-HAMD) is a modified version of the popular depression rating scale developed by Max Hamilton in 1960.

Medication Satisfaction Questionnaire (English)
Medication Satisfaction Questionnaire

Medication Satisfaction Questionnaire (Espanol)
Cuestionario de Satisfaccion con la Medicacion En general, ¿cuán satisfecho está usted con su medicación actual?


The GRID Hamilton Rating Scale for Depression (GRID-HAMD) is a modified version of the popular depression rating scale developed by Max Hamilton in 1960. One difficulty in administering earlier versions of the HAMD is that two important dimensions of illness severity—intensity and frequency—must be taken into account when making a single rating. However, there are no guidelines for the rater to help determine the contribution of both to symptom severity. The GRID-HAMD was designed to permit the rater to consider the dimensions of intensity and frequency independently for each relevant item in the scale.

Symptom intensity is considered on the "vertical axis" and symptom frequency on the "horizontal axis." Symptom intensity, which includes degree of symptom magnitude as well as subjective distress and functional impairment, is rated as "absent, mild, moderate, severe, and very severe." Symptom frequency is rated as "absent, occasional, much of the time, and almost all of the time." Examples of degrees of intensity and frequency are provided in the GRID itself.

The GRID-HAMD was designed to both simplify and standardize administration and scoring in clinical practice and research. Item descriptions have been modified to enhance the reliability of the scale and its relevance to depressed outpatients. The GRID-HAMD includes a structured interview guide and set of rating conventions. Like many other psychiatric semi-structured interviews, the GRID-HAMD is intended for use by individuals who have received adequate training in the assessment of mood in a depressed population and in the use of the GRID-HAMD itself.

Assessing Onset of Treatment Benefit in Depression and Anxiety

Methods for characterizing the onset of treatment benefit in major depressive disorder and generalized anxiety disorder have been studied for some time, yet there is no uni- versal agreement as to the best approaches. Our purpose is to summarize the conceptual framework underlying modern methods for characterizing onset and detailed approaches for which there is consensus from the perspective of a clinician, clini- cal researcher, and statistician. Possible alternatives to unresolved issues are discussed.

There were experts from academia, the pharmaceutical industry, and the US Food and Drug Administration who met on April 19, 2007, to consider the issues. Many others from sponsoring firms observed the proceedings.

A series of papers was presented at a consensus meeting and, after discussions, a sense of the participants was obtained. A small group subsequently reviewed the material and articles from the literature and prepared this article, which was reviewed by all of the participants.

The elements that form the basis for describing onset of treatment benefit include defining a clinical event or measurable threshold that validly signals that a treatment has begun to provide clinically meaningful and sustained im- provement and utilizing methods for estimating the probability of crossing the onset threshold, the distribution of time to onset for those who do cross, and when to alter or change interventions if the treatment is unsuccessful.